Potential preventive properties of GLP-1 receptor agonists against prostate cancer: a nationwide cohort study
Authors' conclusion
GLP-1RA use was inversely associated with prostate cancer risk compared with use of basal insulin in the 'per-protocol' analysis. Older men and patients with CVD exhibited stronger inverse associations in both the 'ITT' and 'per-protocol' analyses. Our results may indicate that GLP-1RA use could protect against prostate cancer.
Study context
- Population
- All men in Denmark aged ≥50 years who commenced GLP-1 RAs or basal insulin during 2007–2019697 prostate cancers
- Participants
- 14,206 vs 21,756
- Exposure
- GLP-1 RA vs basal insulin
- GLP-1RAsn = 14,206
- Basal insulinn = 21,756reference
- Outcome
- Incident prostate cancer
- Follow-up
- Mean about 5 years
Methodological detailsactive-comparator, new-user design
- Active-comparator, new-user design
Main finding
As reported in the abstract
GLP-1RAs vs Basal insulinAdjusted hazard ratio (95% CI)
ITT analysis
0.91(0.73–1.14)
Per-protocol analysis
0.80(0.64–1.01)
Observational data: associations, not effects.
Further findings
Incident prostate cancer, subgroup: older men (≥70 years), GLP-1RA vs basal insulin
- 'ITT' HR
- 0.56 (0.38, 0.82) (95% CI)
- 'per-protocol' HR
- 0.47 (0.30, 0.74) (95% CI)
- Stronger inverse associations
Incident prostate cancer, subgroup: patients with CVD, GLP-1RA vs basal insulin
- 'ITT' HR
- 0.75 (0.53, 1.06) (95% CI)
- 'per-protocol' HR
- 0.60 (0.39, 0.91) (95% CI)
- Stronger inverse associations
Original publication
Potential preventive properties of GLP-1 receptor agonists against prostate cancer: a nationwide cohort study. Diabetologia. Published 3 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →